Clover Narrows Loss as It Cuts Costs and Refocuses on Respiratory Vaccines

Clover Biopharmaceuticals Ltd. ( (HK:2197) ) just unveiled an announcement.

Clover Biopharmaceuticals reported a sharp contraction in revenue to RMB3.5 million in 2025, mainly from a return-rate adjustment on earlier AdimFlu-S (QIS) sales, while cash and bank balances fell by roughly half to RMB271.4 million amid loan repayments, R&D spending and operating costs. The company cut selling, administrative and other expenses significantly, helping narrow its annual loss to RMB205.1 million from RMB903.4 million, as it wound down China commercialization of AdimFlu-S, streamlined operations, and concentrated resources on respiratory vaccine candidates, with provisions for COVID-19 raw materials no longer weighing on results.

The drop in other income reflected the absence of one-off items such as waived trade payables and final CEPI funding, partly offset by higher government grants and foreign-exchange gains. Overall, the results underscore a strategic shift from legacy COVID-19 and flu vaccine commercialization toward a leaner, R&D-focused model, with tighter cost controls but a notably reduced liquidity buffer that may heighten investor attention on funding needs and execution of its respiratory vaccine strategy.

The most recent analyst rating on (HK:2197) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.

More about Clover Biopharmaceuticals Ltd.

Clover Biopharmaceuticals Ltd. is a Hong Kong-listed biopharmaceutical company focused on developing and commercializing vaccines, particularly respiratory vaccine candidates. The group has previously marketed AdimFlu-S (QIS) in mainland China but has since terminated commercial activities for that product as it refocuses on pipeline priorities and cost efficiency.

Average Trading Volume: 3,948,072

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.87B

For an in-depth examination of 2197 stock, go to TipRanks’ Overview page.